WA-based Parse Biosciences Acquired Biomage. With the acquisition, customers will have access to a richer suite of single cell data analysis tools through an intuitive interface.

By pairing Biomage’s powerful data analysis tools with Parse’s Evercode combinatorial barcoding technology, researchers gain deeper insights with a dramatically reduced analysis time.

Read also –  WA-based Fullcast Secures $34M in Seed Funding

Biomage hosts and supports the largest community instance of Cellenics®, a cloud-based single cell RNA sequencing data analysis platform. Through an intuitive user interface, the Cellenics platform brings powerful analysis tools to researchers without the need for bioinformatics expertise.

Parse Biosciences co-founder and CTO Charles Roco said, “The platform has quickly become a trusted resource for single cell researchers around the world, Integrating the software into Parse’s portfolio of offerings will give our customers access to rich, dynamic exploration of single cell data in a shorter amount of time than anything currently available.”

Biomage co-founder and CEO Adam Kurkiewicz said, “The combination of Parse’s scalability – which allows for exponentially more experiments than other single cell technologies – and Biomage’s technology to speed analysis is an unbeatable combination that is going to have wide-ranging, positive implications for the single cell community,”.

About Parse Biosciences

Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach is enabling groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.

Read also – MO-based Clever Real Estate Acquired Gravy Technologies

About Biomage

They at Biomage have a strong commitment to advancing human health. Their single-cell analytics tool, Cellscope, is helping researchers unlock previously unattainable insights into intricate datasets, identify novel therapeutic targets, and provide profound biological insights.

Read also –  California-based Mercor Secures $3.6M in Funding